Likitanci da magunguna · Bayanan hukuma
EMA ta ba da shawarar amincewa da Zybrivo (sintilimab) don NSCLC
A ranar 12 ga Nuwamba 2026, Kwamitin CHMP na EMA ya amince da ra'ayi mai kyau yana ba da shawarar izinin talla don Zybrivo (sintilimab). Mai nema Fortvita yana neman amincewa da wannan magani don magance non-squamous non-small cell lung cancer a cikin manya. Wannan yana faɗaɗa zaɓuɓɓukan rigakafi don wannan takamaiman nau'in ciwon daji.
Asalin tushe
Karanta tushen — ema.europa.eu ↗Muna haɗawa da ainihin mai wallafawa. Taƙaitawar da ke sama jagora ce kawai; karanta asalin don cikakken bayani.